ClinicalTrials.gov
public full text
Public Domain
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis#892741
- Efficacy Evaluation and Cutaneous Acceptability of the Lipikar Med Product on Subjects With Atopic Dermatitis#1085715
- Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream#1128128
- A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis#1072105
- Topical febuxostat attenuates imiquimod-induced psoriasiform dermatitis and modulates NFE2L2 (NRF2)/NLRP3 mRNA expression#667422
Record · ID 1309557
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive